Cargando…

A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients

Solid Organ Transplant (SOT) recipients are at significant higher risk for COVID-19 and due to immunosuppressive medication, the immunogenicity after vaccination is suboptimal. In the previous studies, booster method showed significant benefit in this population. In the current study, we compared us...

Descripción completa

Detalles Bibliográficos
Autores principales: Natori, Yoichiro, Martin, Eric, Mattiazzi, Adela, Arosemena, Leopoldo, Ortigosa-Goggins, Mariella, Shobana, Sivan, Roth, David, Kupin, Warren Lee, Burke, George William, Ciancio, Gaetano, Morsi, Mahmoud, Phancao, Anita, Munagala, Mrudula R., Butrous, Hoda, Manickavel, Suresh, Sinha, Neeraj, Sota, Katherine, Pallikkuth, Suresh, Bini, Julia, Simkins, Jacques, Anjan, Shweta, Vianna, Rodrigo M., Guerra, Giselle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113439/
https://www.ncbi.nlm.nih.gov/pubmed/37091963
http://dx.doi.org/10.3389/ti.2023.10938
_version_ 1785027837205413888
author Natori, Yoichiro
Martin, Eric
Mattiazzi, Adela
Arosemena, Leopoldo
Ortigosa-Goggins, Mariella
Shobana, Sivan
Roth, David
Kupin, Warren Lee
Burke, George William
Ciancio, Gaetano
Morsi, Mahmoud
Phancao, Anita
Munagala, Mrudula R.
Butrous, Hoda
Manickavel, Suresh
Sinha, Neeraj
Sota, Katherine
Pallikkuth, Suresh
Bini, Julia
Simkins, Jacques
Anjan, Shweta
Vianna, Rodrigo M.
Guerra, Giselle
author_facet Natori, Yoichiro
Martin, Eric
Mattiazzi, Adela
Arosemena, Leopoldo
Ortigosa-Goggins, Mariella
Shobana, Sivan
Roth, David
Kupin, Warren Lee
Burke, George William
Ciancio, Gaetano
Morsi, Mahmoud
Phancao, Anita
Munagala, Mrudula R.
Butrous, Hoda
Manickavel, Suresh
Sinha, Neeraj
Sota, Katherine
Pallikkuth, Suresh
Bini, Julia
Simkins, Jacques
Anjan, Shweta
Vianna, Rodrigo M.
Guerra, Giselle
author_sort Natori, Yoichiro
collection PubMed
description Solid Organ Transplant (SOT) recipients are at significant higher risk for COVID-19 and due to immunosuppressive medication, the immunogenicity after vaccination is suboptimal. In the previous studies, booster method showed significant benefit in this population. In the current study, we compared using a mix-and-match method vs. same vaccine as a third dose in SOT recipients. This was a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs. JNJ-78436735 vaccine as the third dose after two doses of BNT162b2 vaccine. We included adult SOT recipients with functional graft who had received two doses of BNT162b2 vaccine. Participants were randomly assigned to receive either BNT162b2 or JNJ-78436735 in one-to-one ratio. Primary outcome was SARS-CoV-2 IgG positivity at 1 month after the third dose. Sixty SOT recipients, including 36 kidney, 12 liver, 2 lung, 3 heart, and 5 combined transplants, were enrolled, and 57 recipients were analyzed per protocol. There were no statistically significant differences between the two vaccine protocols for IgG positivity (83.3% vs. 85.2% for BNT162b2 and JNJ-78436735, respectively, p = 0.85, Odds Ratio 0.95, 95% Confidence Interval 0.23–4.00). Comparison of the geometric mean titer demonstrated a higher trend with BNT162b2 (p = 0.09). In this pilot randomized controlled trial comparing mix and match method vs. uniform vaccination in SOT recipients, both vaccines were safely used. Since this was a small sample sized study, there was no statistically significant difference in immunogenicity; though, the mix and match method showed relatively lower geometric mean titer, as compared to uniform vaccine. Further studies need to be conducted to determine duration of this immunogenicity. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT05047640?term=20210641&draw=2&rank=1, identifier 20210641.
format Online
Article
Text
id pubmed-10113439
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101134392023-04-20 A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients Natori, Yoichiro Martin, Eric Mattiazzi, Adela Arosemena, Leopoldo Ortigosa-Goggins, Mariella Shobana, Sivan Roth, David Kupin, Warren Lee Burke, George William Ciancio, Gaetano Morsi, Mahmoud Phancao, Anita Munagala, Mrudula R. Butrous, Hoda Manickavel, Suresh Sinha, Neeraj Sota, Katherine Pallikkuth, Suresh Bini, Julia Simkins, Jacques Anjan, Shweta Vianna, Rodrigo M. Guerra, Giselle Transpl Int Health Archive Solid Organ Transplant (SOT) recipients are at significant higher risk for COVID-19 and due to immunosuppressive medication, the immunogenicity after vaccination is suboptimal. In the previous studies, booster method showed significant benefit in this population. In the current study, we compared using a mix-and-match method vs. same vaccine as a third dose in SOT recipients. This was a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs. JNJ-78436735 vaccine as the third dose after two doses of BNT162b2 vaccine. We included adult SOT recipients with functional graft who had received two doses of BNT162b2 vaccine. Participants were randomly assigned to receive either BNT162b2 or JNJ-78436735 in one-to-one ratio. Primary outcome was SARS-CoV-2 IgG positivity at 1 month after the third dose. Sixty SOT recipients, including 36 kidney, 12 liver, 2 lung, 3 heart, and 5 combined transplants, were enrolled, and 57 recipients were analyzed per protocol. There were no statistically significant differences between the two vaccine protocols for IgG positivity (83.3% vs. 85.2% for BNT162b2 and JNJ-78436735, respectively, p = 0.85, Odds Ratio 0.95, 95% Confidence Interval 0.23–4.00). Comparison of the geometric mean titer demonstrated a higher trend with BNT162b2 (p = 0.09). In this pilot randomized controlled trial comparing mix and match method vs. uniform vaccination in SOT recipients, both vaccines were safely used. Since this was a small sample sized study, there was no statistically significant difference in immunogenicity; though, the mix and match method showed relatively lower geometric mean titer, as compared to uniform vaccine. Further studies need to be conducted to determine duration of this immunogenicity. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT05047640?term=20210641&draw=2&rank=1, identifier 20210641. Frontiers Media S.A. 2023-04-05 /pmc/articles/PMC10113439/ /pubmed/37091963 http://dx.doi.org/10.3389/ti.2023.10938 Text en Copyright © 2023 Natori, Martin, Mattiazzi, Arosemena, Ortigosa-Goggins, Shobana, Roth, Kupin, Burke, Ciancio, Morsi, Phancao, Munagala, Butrous, Manickavel, Sinha, Sota, Pallikkuth, Bini, Simkins, Anjan, Vianna and Guerra. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Natori, Yoichiro
Martin, Eric
Mattiazzi, Adela
Arosemena, Leopoldo
Ortigosa-Goggins, Mariella
Shobana, Sivan
Roth, David
Kupin, Warren Lee
Burke, George William
Ciancio, Gaetano
Morsi, Mahmoud
Phancao, Anita
Munagala, Mrudula R.
Butrous, Hoda
Manickavel, Suresh
Sinha, Neeraj
Sota, Katherine
Pallikkuth, Suresh
Bini, Julia
Simkins, Jacques
Anjan, Shweta
Vianna, Rodrigo M.
Guerra, Giselle
A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
title A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
title_full A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
title_fullStr A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
title_full_unstemmed A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
title_short A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
title_sort pilot single-blinded, randomized, controlled trial comparing bnt162b2 vs. jnj-78436735 vaccine as the third dose after two doses of bnt162b2 vaccine in solid organ transplant recipients
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113439/
https://www.ncbi.nlm.nih.gov/pubmed/37091963
http://dx.doi.org/10.3389/ti.2023.10938
work_keys_str_mv AT natoriyoichiro apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT martineric apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT mattiazziadela apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT arosemenaleopoldo apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT ortigosagogginsmariella apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT shobanasivan apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT rothdavid apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT kupinwarrenlee apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT burkegeorgewilliam apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT cianciogaetano apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT morsimahmoud apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT phancaoanita apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT munagalamrudular apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT butroushoda apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT manickavelsuresh apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT sinhaneeraj apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT sotakatherine apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT pallikkuthsuresh apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT binijulia apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT simkinsjacques apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT anjanshweta apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT viannarodrigom apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT guerragiselle apilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT natoriyoichiro pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT martineric pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT mattiazziadela pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT arosemenaleopoldo pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT ortigosagogginsmariella pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT shobanasivan pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT rothdavid pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT kupinwarrenlee pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT burkegeorgewilliam pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT cianciogaetano pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT morsimahmoud pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT phancaoanita pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT munagalamrudular pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT butroushoda pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT manickavelsuresh pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT sinhaneeraj pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT sotakatherine pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT pallikkuthsuresh pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT binijulia pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT simkinsjacques pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT anjanshweta pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT viannarodrigom pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients
AT guerragiselle pilotsingleblindedrandomizedcontrolledtrialcomparingbnt162b2vsjnj78436735vaccineasthethirddoseaftertwodosesofbnt162b2vaccineinsolidorgantransplantrecipients